Prexton Therapeutics

Prexton Therapeutics is the first spin-off company from EPP Fund. The company is developing programs in Parkinson’s disease focused on targeting the metabotropic glutamate receptors mGluR3 and mGluR4. Prexton Therapeutics is based in Geneva, Switzerland.

Team Members
more about
Jasper Bos
more about
Edward Kliphuis
Latest News Entry
Parkinson’s disease: Prexton announces initiation of phase II clinical testing

Study will evaluate first-in class treatment in six European countries

all portfolio news